Loading clinical trials...
Loading clinical trials...
A 6 and 12 month safety and immunogenicity study of participants in study GPNV-001, a novel whole-cell pneumococcal vaccine.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
GPN Vaccines
NCT06998251 · Pneumococcal Infections, Respiratory Syncytial Virus (RSV) Infection, and more
NCT04214444 · Pneumococcal Infections, Lymphoma, Large B-Cell, Diffuse
NCT06822907 · Acute Febrile Illness, Pneumococcal Infections
NCT05920499 · Pneumococcal Infections
NCT03276754 · Pneumococcal Infections, COPD
University of Adelaide
Adelaide, South Australia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions